Gyder Surgical announces first commercial surgical cases in the United States performed by Dr. Paul M. Lombardi, M.D., at the Tri-County Orthopedics Joint Replacement Institute outpatient center

1 month ago

PALO ALTO, Calif. and MULGRAVE, Australia, Feb. 22, 2026 (GLOBE NEWSWIRE) -- Gyder Surgical, a MedTech company specializing in intuitive, non-invasive…

Dassault Systmes CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systmes

1 month ago

Press ReleaseVELIZY-VILLACOUBLAY, France — February 21, 2026 Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors…

Weaviate Launches Agent Skills to Empower AI Coding Agents

1 month ago

Amsterdam, Netherlands, Feb. 21, 2026 (GLOBE NEWSWIRE) -- February 20, 2026 – Weaviate, the leading open-source AI database, today announced…

Seedance2ai.online Launches All-in-One Seedance 2.0 Video Creation Platform With Free Tier for Global Creators

1 month ago

LOS ANGELES, CA, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Seedance2ai.online today announced the public launch of its video creation platform…

Amdavad 2030 Opens Doors to Global Business Opportunities

1 month ago

West Midlands Mayor Leads Strategic UK Delegation to Translate Sporting Ambition into Long-Term Economic PartnershipsAHMEDABAD, India, Feb. 21, 2026 /PRNewswire/…

Thermobalancing therapy emerges as drug-free option for BPH, chronic prostatitis, back pain and kidney stones

1 month ago

Oxford, UK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Therapeutic Dr Allen’s Devices are designed to treat different chronic health conditions,…

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

1 month ago

February 20, 2026 15:10 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults

1 month ago

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If…

LATHAM & WATKINS ELECTS 22 NEW PARTNERS

1 month ago

Promotions from counsel include skilled practitioners advising clients across transactional, litigation, and regulatory matters.NEW YORK, Feb. 20, 2026 /PRNewswire/ --…

VERSES Announces Filing of Quarterly Report on Form 10-Q for the Three and Nine-Months Ended December 31, 2025

1 month ago

February 20, 2026 19:11 ET  | Source: VERSES AI Inc. VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- VERSES…